INTRODUCTION: Measuring bleeding in critical care trials is challenging. We determined the reliability of adjudicated bleeding assessments in a large thromboprophylaxis trial in the intensive care unit (ICU). MATERIALS AND METHODS:PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) was an international randomized controlled trial that compared dalteparin to unfractionated heparin for the prevention of deep vein thrombosis in the ICU. Daily bleeding data were collected prospectively using a validated tool. Bleeds were adjudicated in duplicate by 2 of 4 members comprising a central adjudication committee. Bleeds were stratified by severity and study drug, then randomly assigned to adjudicator pairs. Adjudicators were blinded to treatment allocation, study centre and peer-assessments. We calculated agreement on bleeding severity and examined the effect of adjudication on overall trial results. RESULTS: In PROTECT, 491 patients had bleeding events including 208 with major bleeding and 283 with minor bleeding only. Of 491 patients, 446 were adjudicated in duplicate: 182 with major, 250 with minor and 14 with no bleeding. After adjudication, 52 of 244 bleeds were downgraded to minor; whereas only 15 of 244 were upgraded to major. Overall agreement among adjudicators was excellent (crude agreement=86.3%; kappa=0.76). Hazard ratios for major or any bleeding with dalteparin or unfractionated heparin were similar when analyzed using non-adjudicated events. CONCLUSIONS: Major bleeds were sometimes over-called by research coordinators in a large ICU thromboprohylaxis trial. Adjudicator agreement was excellent. Central adjudication allowed reliable bleeding assessment and enhanced the rigor and validity of this major safety outcome.
RCT Entities:
INTRODUCTION: Measuring bleeding in critical care trials is challenging. We determined the reliability of adjudicated bleeding assessments in a large thromboprophylaxis trial in the intensive care unit (ICU). MATERIALS AND METHODS: PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) was an international randomized controlled trial that compared dalteparin to unfractionated heparin for the prevention of deep vein thrombosis in the ICU. Daily bleeding data were collected prospectively using a validated tool. Bleeds were adjudicated in duplicate by 2 of 4 members comprising a central adjudication committee. Bleeds were stratified by severity and study drug, then randomly assigned to adjudicator pairs. Adjudicators were blinded to treatment allocation, study centre and peer-assessments. We calculated agreement on bleeding severity and examined the effect of adjudication on overall trial results. RESULTS: In PROTECT, 491 patients had bleeding events including 208 with major bleeding and 283 with minor bleeding only. Of 491 patients, 446 were adjudicated in duplicate: 182 with major, 250 with minor and 14 with no bleeding. After adjudication, 52 of 244 bleeds were downgraded to minor; whereas only 15 of 244 were upgraded to major. Overall agreement among adjudicators was excellent (crude agreement=86.3%; kappa=0.76). Hazard ratios for major or any bleeding with dalteparin or unfractionated heparin were similar when analyzed using non-adjudicated events. CONCLUSIONS: Major bleeds were sometimes over-called by research coordinators in a large ICU thromboprohylaxis trial. Adjudicator agreement was excellent. Central adjudication allowed reliable bleeding assessment and enhanced the rigor and validity of this major safety outcome.
Authors: Nick Daneman; Asgar H Rishu; Wei Xiong; Sean M Bagshaw; Deborah J Cook; Peter Dodek; Richard Hall; Anand Kumar; Francois Lamontagne; Francois Lauzier; John C Marshall; Claudio M Martin; Lauralyn McIntyre; John Muscedere; Steven Reynolds; Henry T Stelfox; Robert A Fowler Journal: Trials Date: 2015-04-18 Impact factor: 2.279
Authors: Menaka Pai; Neill K J Adhikari; Marlies Ostermann; Diane Heels-Ansdell; James D Douketis; Yoanna Skrobik; Ismael Qushmaq; Maureen Meade; Gordon Guyatt; William Geerts; Michael W Walsh; Mark A Crowther; Jan O Friedrich; Lisa Burry; Rinaldo Bellomo; Nilton Brandão da Silva; Rubens Costa Filho; Michael J Cox; Suzana Alves Silva; Deborah J Cook Journal: PLoS One Date: 2018-06-01 Impact factor: 3.240
Authors: Jaeyoung Cho; Sun Mi Choi; Su Jong Yu; Young Sik Park; Chang-Hoon Lee; Sang-Min Lee; Jae-Joon Yim; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Jinwoo Lee Journal: Korean J Intern Med Date: 2016-01-25 Impact factor: 2.884
Authors: Jennie Johnstone; Maureen Meade; John Marshall; Daren K Heyland; Michael G Surette; Dawn Me Bowdish; Francois Lauzier; Lehana Thebane; Deborah J Cook Journal: Pilot Feasibility Stud Date: 2015-05-24
Authors: Kimberly I Mills; Ben D Albert; Lori J Bechard; Christopher P Duggan; Aditya Kaza; Seth Rakoff-Nahoum; Hera Vlamakis; Lynn A Sleeper; Jane W Newburger; Gregory P Priebe; Nilesh M Mehta Journal: Trials Date: 2020-06-29 Impact factor: 2.728
Authors: Nick Daneman; Asgar H Rishu; Ruxandra L Pinto; Yaseen M Arabi; Deborah J Cook; Richard Hall; Shay McGuinness; John Muscedere; Rachael Parke; Steven Reynolds; Benjamin Rogers; Yahya Shehabi; Robert A Fowler Journal: BMJ Open Date: 2020-05-11 Impact factor: 2.692
Authors: Waleed Alhazzani; Gordon Guyatt; John C Marshall; Richard Hall; John Muscedere; Francois Lauzier; Lehana Thabane; Mohammed Alshahrani; Shane W English; Yaseen M Arabi; Adam M Deane; Tim Karachi; Bram Rochwerg; Simon Finfer; Nick Daneman; Nicole Zytaruk; Diane Heel-Ansdell; Deborah Cook; On Behalf Of Journal: Ann Saudi Med Date: 2016 Nov-Dec Impact factor: 1.526
Authors: Donald M Arnold; Francois Lauzier; Martin Albert; David Williamson; Na Li; Ryan Zarychanski; Chip Doig; Lauralyn McIntyre; Andreas Freitag; Mark Crowther; Lois Saunders; France Clarke; Rinaldo Bellomo; Ismael Qushmaq; Renato D Lopes; Diane Heels-Ansdell; Kathryn Webert; Deborah Cook Journal: Res Pract Thromb Haemost Date: 2017-05-31